王燕婷 陈丽影 周益美

【摘要】 目的：探讨加味二妙散联合重组人干扰素α2b对低级别宫颈鳞状上皮内病变患者的疗效，为患者的诊疗提供指导。方法：选取2016年6月-2018年2月泉州市妇幼保健院接诊的180例低级别宫颈鳞状上皮内病变（CIN Ⅰ）患者展开研究，随机分为中药联合干扰素组、干扰素组、对照组（予以临床密切随访），每组60例，比较三组患者6个月及1年病变逆转率。结果：三组患者随访6个月时病变逆转率比较差异无统计学意义（P>0.05），随访1年时，中药联合干扰素组、干扰素组病变逆转率明显优于对照组（P<0.05），且中药联合干扰素组疗效最佳（P<0.05）。中药联合干扰素组和干扰素组不良反应发生率差异无统计学意义（P>0.05）。结论：加味二妙散联合重组人干扰素α2b治疗CIN Ⅰ患者效果显著，值得应用推广。

【关键词】 加味二妙散 重组人干扰素α2b 低级别宫颈鳞状上皮内病变 人乳头状瘤病毒 病变逆转率

doi：10.14033/j.cnki.cfmr.2019.29.012 文献标识码 B 文章编号 1674-6805（2019）29-00-03

[Abstract] Objective： To investigate the efficacy of Jiawei Ermiao San combined with Recombinant Human Interferon α2b in patients with low grade cervical squamous intraepithelial lesions， and provide guidance for the patient's diagnosis and treatment. Method： A study was conducted on 180 patients with low-grade cervical squamous intraepithelial lesion （CIN Ⅰ） who were admitted to our hospital from June 2016 to February 2018 in the Maternal and Child Health Hospital of Quanzhou City. They were randomly divided into the traditional Chinese medicine combined with interferon group， the interferon group， and the control group （close clinical follow-up）， 60 cases in each group. The reversal rate of lesions were compared between the three groups of patients at 6 months and 1 year. Result： There was no significant difference in the rate of reversal of lesions between the three groups at 6 months （P>0.05）. After 1 year of follow-up， the reversal rate of the traditional Chinese medicine combined with interferon group and the interferon group was significantly better than that of the control group （P<0.05）. The traditional Chinese medicine combined with interferon group was the best （P<0.05）. There was no significant difference in the incidence of adverse reactions between the traditional Chinese medicine combined with interferon group and the interferon group （P>0.05）. Conclusion： The effect of Jiawei Ermiao San combined with Recombinant Human Interferon α2b in the treatment of CIN Ⅰ is significant. It is worth applying for promotion.

[Key words] Jiawei Ermiao San Recombinant Human Interferon Alpha 2b Low grade cervical squamous intraepithelial lesions Human papillomavirus Pathological change reversal rate

First-authors address： The Maternal and Child Health Hospital of Quanzhou City·Childrens Hospital， Quanzhou 362000， China

宫颈癌是女性中常见的恶性肿瘤，发病率仅次于乳腺癌，且近年来有趋于年轻化的表現，多数宫颈癌患者是由宫颈癌前病变进展而成，宫颈癌前病变根据病变程度不同可分别低级别宫颈鳞状上皮内病变（CIN Ⅰ）和高级别宫颈鳞状上皮内病变（CIN Ⅱ、CIN Ⅲ期），其中CIN Ⅰ期是宫颈病变最早期的一个阶段，远期可出现进展、退化或者维持不变，此类患者经病理学检查主要表现为上皮下1/3层细胞核有增大表现，核染色轻度加深，核分裂象较少，细胞成极性正常状态[1]。而阻断和逆转宫颈癌前病变是预防宫颈癌的关键，而宫颈癌前病变的发生和高危型人乳头状瘤病毒（HPV）持续性感染密切相关 [2]。重组人干扰素α2b是目前该病中常用的药物治疗方式，主要作用是促进抗病毒蛋白合成能力、消除细胞炎症、改善细胞免疫功能等。中医……